Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 µg ethinyl estradiol and 3 mg drospirenone

By Milsom I.   Lete I.   Bjertnaes A.   Rokstad K.   Lindh I.   Gruber C.J.   Birkhäuser M.H.   Aubeny E.   Knudsen T.   Bastianelli C.  

Human Reproduction, Vol. 21, Iss. 9, 2006-09 ,pp. : 2304-2311

Oxford University Press

Access to resources Recommend Favorite

Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 g ethinylestradiol and 150 g levonorgestrel: a randomized trial

By Oddsson K.  

Human Reproduction, Vol. 20, Iss. 2, 2005-02 ,pp. : 557-562

Oxford University Press

Access to resources Recommend Favorite

Ethinylestradiol/Drospirenone: A Review of its Use as an Oral Contraceptive

By Keam S.J.   Wagstaff A.J.  

Treatments in Endocrinology, Vol. 2, Iss. 1, 2003-01 ,pp. : 39-61

Adis International

Access to resources Recommend Favorite

A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinilestradiol 3 mg/20 mcg

By Mabrouk Mohamed   Solfrini Serena   Frascà Clarissa   Del Forno Simona   Montanari Giulia   Ferrini Giulia   Paradisi Roberto   Seracchioli Renato  

Gynecological Endocrinology, Vol. 28, Iss. 6, 2012-06 ,pp. : 451-454

Informa Healthcare

Access to resources Recommend Favorite

A Comparison of the Cycle Control, Safety, and Efficacy Profile of a 21-Day Regimen of Ethinylestradiol 20g and Drospirenone 3mg with a 21-Day Regimen of Ethinylestradiol 20g and Desogestrel 150g

By Gruber Doris M.  

Treatments in Endocrinology, Vol. 5, Iss. 2, 2006-01 ,pp. : 115-121

Adis International

Access to resources Recommend Favorite